Shares of Freenome (NASDAQ:FRNM – Get Free Report) reached a new 52-week low during trading on Friday. The company traded as low as $9.90 and last traded at $9.9640, with a volume of 280,281 shares traded. The stock had previously closed at $10.47.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. Weiss Ratings began coverage on shares of Freenome in a research note on Monday, August 24th. They issued a “sell (d+)” rating on the stock. TD Cowen assumed coverage on Freenome in a report on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price objective on the stock. Guggenheim started coverage on Freenome in a report on Thursday, August 20th. They set a “buy” rating and a $21.00 target price for the company. Jefferies Financial Group began coverage on Freenome in a report on Monday, August 17th. They set a “buy” rating and a $17.00 target price for the company. Finally, Wall Street Zen raised Freenome to a “sell” rating in a research note on Saturday, September 26th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Freenome presently has an average rating of “Moderate Buy” and an average price target of $18.00.
Check Out Our Latest Research Report on FRNM
Freenome Price Performance
The firm has a 50 day moving average price of $14.52. The firm has a market capitalization of $1.09 billion, a PE ratio of -169.47 and a beta of 0.60.
About Freenome
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at an early stage. Its platform combines artificial intelligence with multiomics, including genomic, epigenomic and proteomic signals found in blood, to identify patterns associated with cancer.
The company has focused its research and clinical development efforts on screening for colorectal cancer and other common cancers. Freenome’s products are intended to support noninvasive screening and may complement or provide an alternative to certain conventional screening methods, subject to regulatory review and approval.
Founded in 2014, Freenome is headquartered in South San Francisco, California.
Featured Articles
- Five stocks we like better than Freenome
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
- Block by Block: Cash App Builds a Stronger Foundation
- Arista Networks Cashes In on the AI Infrastructure Buildout
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
